Mood changes in the menopause transition
People say “stress.” You sense something deeper.
Irritability, sudden anxiety, or emotional swings are common in perimenopause - and are often misread as pure overload or “clinical depression” without a hormonal lens. About 40–50% of women describe a clear change in emotional resilience. This is not weakness; it reflects neuroendocrine change. In the menopause transition, hormones interact directly with brain signaling. Understanding that internal medicine context helps restore stability and joy.
of women report a clear change in emotional resilience during midlife transition. [3]
The internal medicine lens
“Emotional lability in midlife is often biochemistry - not a moral failure. When we address biology with precision, stability usually improves.”
Hormones modulate neurotransmission. Progesterone metabolites can support GABAergic calming signals; when progesterone falls in the menopause transition, that buffer can thin.
Estrogen influences serotonin dynamics; fluctuating estrogen can destabilize mood and irritability in susceptible people.
Irritability and inner tension often reflect sympathetic overdrive - “fight or flight” stuck in the on position.
It is essential to separate hormone-linked symptoms from thyroid disease and nutrient issues (B12, iron) - which can mimic anxiety and depression. Sleep loss and cognitive symptoms also amplify emotional instability.
Fatigue is not a separate mystery - it is often part of the same pattern and worsens reactivity.
Many women feel emotionally steadier after transition; targeted support during the window can shorten suffering.
Why Dr. Lorenz?
I place mood symptoms in the context of hormones, thyroid, nutrients, sleep, and stress physiology - and differentiate hormone-linked distress from primary major depression when safety requires it.
My two-visit pathway includes careful history, focused labs (hormones, thyroid, B vitamins, magnesium), and a collaborative plan (see About).
What could be going on?
Differential diagnoses
Mood symptoms are often multifactorial. Thorough evaluation identifies what is treatable - not only what is “in your head.”
Thyroid dysfunction
Hyperthyroidism can cause anxiety; hypothyroidism can cause low mood and fatigue. (See thyroid.)
Vitamin B12 deficiency
B12 is essential for nerve function; deficiency can mimic irritability and depression.
Iron deficiency
Low ferritin causes fatigue that is often mistaken for depression.
Major depression
When criteria are met, treatment pathways differ from hormone-focused care - accurate distinction matters for safety.
Structured evaluation targets causes - not labels.
What actually helps?
Evidence-based options
This section reflects current guideline recommendations [1] .
Hormone therapy (HT) [2]
Micronized progesterone can support GABAergic tone; estrogen can stabilize serotonin-related vulnerability in selected patients. [4]
Stress tools & vagal tone
Breathwork and paced recovery reduce sympathetic dominance.
Targeted micronutrients
Magnesium, B6, or omega-3s may help selected patients after labs and context.
We review evidence clearly - without overpromising.
When should you see a doctor?
Many perimenopause symptoms are benign, but the warning signs below should be evaluated promptly:
Suicidal thoughts or intent - seek urgent help immediately
Complete social withdrawal or inability to function
Severe panic with red-flag cardiac symptoms
What patients say about the clarification pathway
I was close to asking for antidepressants… Dr. Lorenz explained how progesterone acts as a neurosteroid in the brain.
N.
Patient, Leipzig
Anonymized case example
Next step
Low mood without a clear “reason”?
I evaluate neuroendocrine contributors to mood change - thyroid, iron, sleep, hormones - without shrugging.
The Perimenopause Clarification is a structured two-visit program with intake, targeted diagnostics, and a written care plan. Package price €490. Lab fees are billed separately by the laboratory (typically €80–280).
Medical sources
This page is not a substitute for individualized medical advice. Key clinical statements link to the sources below.
- [1] NICE Guideline NG23: Menopause - diagnosis and management (NICE, 2024, Leitlinie) Open source
- [2] The 2022 hormone therapy position statement of The North American Menopause Society (Menopause, 2022, Positionspapier) Open source
- [3] Does menopause elevate the risk for developing depression and anxiety? Results from a systematic review. (Australasian Psychiatry, 2023, Systematic Review) Open source
- [4] Symptoms of menopause - global prevalence, physiology and implications (Nature Reviews Endocrinology, 2018, Narrative Review) Open source
Last clinically reviewed 2026-04-15. Reviewed by Dr. med. Christin Lorenz (Ärztin mit internistischem Schwerpunkt).
From the journal
In-depth articles on this topic (German)